Gadoterate meglumine + Gadobutrol
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Diseases
Conditions
Breast Diseases
Trial Timeline
Mar 1, 2021 → Dec 31, 2025
NCT ID
NCT03730051About Gadoterate meglumine + Gadobutrol
Gadoterate meglumine + Gadobutrol is a approved stage product being developed by Guerbet for Breast Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03730051. Target conditions include Breast Diseases.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03730051 | Approved | Completed |
Competing Products
20 competing products in Breast Diseases